European Authorities Recognize Approval Of Zomig Rapimelt
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




European Authorities Recognize Approval Of Zomig Rapimelt

EDEN PRAIRIE, MN -- November 23, 1999 -- CIMA LABS INC. announces that ten European regulatory authorities have agreed to mutually recognize the Swedish approval of Zomig Rapimelt, the OraSolv(R) fast-dissolving version of the AstraZeneca anti-migraine medication. This follows the launch in Sweden earlier in the year.

OraSolv is a patented oral dosage form which incorporates microencapsulated drug ingredients into tablets that dissolve quickly in the mouth. OraSolv is designed to improve taste acceptance and address the difficulty of swallowing traditional tablets and capsules, while offering a convenient oral dosage form that can be taken anywhere and anytime, therefore increasing compliance.

CIMA is a drug delivery company that specializes in oral drug delivery systems to improve patient compliance and drug efficacy. These systems include OraSolv, OraSolv SR/CR and DuraSolv, fast-dissolve technologies, and OraVescent, a dual fast-dissolve/oral transmucosal system for improved oral absorption, targeted site-specific absorption and fast onset of action.

Related Links: Zomig Rapimelt and AstraZeneca .

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities